Are FGFR and IDH1-2 alterations a positive prognostic factor in intrahepatic cholangiocarcinoma? An unresolved issue

Frontiers in Oncology

Oncology

Alessandro Rizzo¹  Angela Dalia Ricci²  Andrea Palloni³  Chiara Deiana⁴  Simona Tavolari⁴  Giovanni Brandi⁴  Linda Galvani⁴ 

[1] IRCCS Istituto Tumori “Giovanni Paolo II” of Bari, Struttura Semplice Dipartimentale di Oncologia Medica per la Presa in Carico Globale del Paziente Oncologico “Don Tonino Bello”, Bari, Italy;Medical Oncology Unit, National Institute of Gastroenterology, “Saverio de Bellis” Research Hospital, Bari, Italy;Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy;Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy;Department of Medicine and Surgical Sciences, University of Bologna, Bologna, Italy;

关键词: FGFR;    IDH;    cholangiocarcinoma;    prognosis;    molecular alteration;   

DOI  :  10.3389/fonc.2023.1137510

 received in 2023-01-04, accepted in 2023-04-06,  发布年份 2023

来源: Frontiers

【 摘 要 】

Despite representing some of the most common and investigated molecular changes in intrahepatic cholangiocarcinoma (iCCA), the prognostic role of FGFR and IDH1/2 alterations still remains an open question. In this review we provide a critical analysis of available literature data regarding this topic, underlining the strengths and pitfalls of each study reported. Despite the overall poor quality of current available studies, a general trend toward a better overall survival for FGFR2 rearrangements and, possibly, for FGFR2-3 alterations can be inferred. On the other hand, the positive prognostic role of IDH1/2 mutation seems much more uncertain. In this scenario, better designed clinical trials in these subsets of iCCA patients are needed in order to get definitive conclusions on this issue.

【 授权许可】

Unknown   
Copyright © 2023 Brandi, Deiana, Galvani, Palloni, Ricci, Rizzo and Tavolari